Organic compounds -- part of the class 532-570 series – Organic compounds – Chalcogen in the nitrogen containing substituent
Reexamination Certificate
2005-02-01
2005-02-01
Raymond, Richard L. (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Chalcogen in the nitrogen containing substituent
C544S006000, C544S058600
Reexamination Certificate
active
06849732
ABSTRACT:
The invention relates to compounds of the formula1:wherein: Z is O or S; V is a divalent radical which together with C* and N forms a ring having six ring atoms, where each of said ring atoms other than C* and N independently is unsubstituted or substituted by a suitable substituent, and at least one of said other ring atoms is a heteroatom selected from O, N and S, and the remainder are carbon atoms; and Ar is an aryl or heteroaryl group; and pharmaceutically acceptable prodrugs, salts and solvates thereof. The invention further relates to pharmaceutically acceptable prodrugs, salts and solvates of these compounds. The invention also relates to methods of inhibiting the activity of metalloproteinases by administering a compound of the formula I or a prodrug, salt or solvate thereof. The invention further relates to pharmaceutical compositions comprising an effective amount of these compounds, prodrugs, salts, and solvates. The invention still further relates to methods and intermediates useful for preparing these compounds, prodrugs, salts, and solvates.
REFERENCES:
patent: 5028604 (1991-07-01), Torizuka et al.
patent: 5116836 (1992-05-01), Fischer et al.
patent: 5256657 (1993-10-01), Singh et al.
patent: 5569665 (1996-10-01), Porter et al.
patent: 5929097 (1999-07-01), Levin et al.
patent: 5932595 (1999-08-01), Bender et al.
patent: 5985900 (1999-11-01), Bender et al.
patent: 195 42 189 (1997-05-01), None
patent: 070389 (1983-01-01), None
patent: 489 577 (1992-06-01), None
patent: 489 579 (1992-06-01), None
patent: 780 386 (1997-06-01), None
patent: 9324449 (1993-12-01), None
patent: 9324475 (1993-12-01), None
patent: 9412169 (1994-06-01), None
patent: 9504735 (1995-02-01), None
patent: 9512603 (1995-05-01), None
patent: 9519961 (1995-07-01), None
patent: 9522966 (1995-08-01), None
patent: 9532944 (1995-12-01), None
patent: 9535276 (1995-12-01), None
patent: 9606074 (1996-02-01), None
patent: 9616027 (1996-05-01), None
patent: 9616931 (1996-06-01), None
patent: 9623791 (1996-08-01), None
patent: 9535275 (1996-12-01), None
patent: 9718194 (1997-05-01), None
patent: 9719068 (1997-05-01), None
patent: 9720824 (1997-06-01), None
patent: 9722587 (1997-06-01), None
patent: 9723459 (1997-07-01), None
patent: 9725969 (1997-07-01), None
patent: 9727174 (1997-07-01), None
patent: 9807697 (1998-02-01), None
patent: 9808815 (1998-03-01), None
patent: 9808825 (1998-03-01), None
Robinson, et al., “Inhibitors of MMP-1: An Examination of P1'Cα Gem-Disubstitution in the Succinamide Hydroxamate Series,” Bioorganic & Medicinal Chemistry Letters, vol. 6, No. 14 (1996), pp. 1719-1724.
Firestone, et al., “Total Synthesis of β-Lactam Antibiotics. IV. Epimerization of 6(7)-Aminopenicillins and-cephalosporins from α to β1, ”Journal of Organic Chemistry, vol. 39, No. 4 (1974), pp. 437-440.
Walker, “Vinylogous Amid s of 2-Methylamino thanol and Their B havior with Lithium Aluminum Hydride, Vinylogous Urethanes of Ethanolamides and Their Ac tylation,” Journal of Organic Chemistry, vol. 27 (1962), pp. 4227-4231.
Cumberbatch, et al., “The Synthesis and Conformation Analysis of a Pair of Diastereoisomeric Cyclic Peptides with cis and trans Amide Bonds, Respectively,” Journal of the Chemical Society, Chemical Communications, No. 7 (1993), pp. 641-642.
Capps, et al., “Novel Catalytic Rearrangements of 2-Vinyl-1,3-Thiazetidines,” Tetrah dron Letters, vol. 25, No. 37 (1984), pp. 4157-4160.
Sakai, et al., “Convenient Syunthesis of 1,4-Thiazane-3-Carboxylic Acid Derivatives,” Chemical and Pharmac utical Bulletin, vol. 29, No. 6, (1981), pp. 1554-1560.
Woessner, Jr., “Matrix metalloproteinases and th ir inhibit rs in connective tissue remodeling”, Th FASEB Journal, vol. 5, No. 8 (1991), pp. 2145-2154.
Freije et al., “Molecular Cloning and Expression of Collagenase-3, a Novel Human Matrix Metalloproteinase Produced by Breast Carcinomas”, The Journal of Biological Chemistry, Vo. 269, No. 24 (1994), ppl. 16766-16773.
Mitchell et al., “cloning, Expression, and Type II collagenolytic Activity of Matrix Metalloproteinase-13 from Human Osteoarthritic Cartilage,” The Journal of Clinical Investigation, vol. 97, No. 3 (1996), pp. 761-768.
Ray et al., “Matrix m talloproteinases and malignant dis as : r cent devlopments,” Expert Opinion on Investigational Drugs, vol. 5, No. 3 (1996), pp. 323-335.
Birkedal-Hansen, “Host-Mediated Extracellular Matrix Destruction by Metalloproteinas s,” Molecular Pathogenis of Periodontal Disease (1994), pp. 191-202.
Gijbels et al., “Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neuroligical disorders,” Journal of Neuroimmunology, 41 (1992), pp. 29-34.
O'Day et al., “Differences in Response in Vivo to Amphotericin B Among Candida albicans Strains”, Investigative Ophthalmology & Visual Scienc , vol. 32, No. 5 (1991), pp. 1569-1572.
Bender Steven L.
Dagnino, Jr. Raymond
Deason Michael E.
Melnick Michael J.
Zook Scott E.
LandOfFree
Metalloproteinase inhibitors, pharmaceutical compositions... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metalloproteinase inhibitors, pharmaceutical compositions..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metalloproteinase inhibitors, pharmaceutical compositions... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3459450